---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-000338"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2023-01-19T23:59:59+00:00"
generated_at: "2026-06-20T13:10:29.792499+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics reports positive Phase 2 data for CTX-009 in biliary tract cancers; ORR 37.5%

## Summary
- CTX-009 + paclitaxel achieved 37.5% ORR in 24 patients; second-line sub-group ORR 63.6% (7/11 PRs).
- Median PFS 9.4 months, median OS 12.5 months; data to be presented at ASCO GI on Jan 20, 2023.
- Randomized Phase 2/3 trial (up to 150 patients) initiated in US; may enable BLA submission in H2 2024.
- Safety consistent with prior studies; Grade 3+ TEAEs included decreased neutrophils (83.3%), hypertension (16.7%).
- Investor webcast scheduled for Jan 23 at 8:30am ET.

## SEC filing metadata
- accession: 0001171843-23-000338
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2023-01-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184323000338/0001171843-23-000338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184323000338/f8k_011923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-000338
- JSON: https://secwatch.observer/filing/0001171843-23-000338.json
- Plain text: https://secwatch.observer/filing/0001171843-23-000338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.